Allogene Therapeutics received a Sell rating and price target from J.P. Morgan analyst Brian Cheng today. The company’s shares closed yesterday at $1.27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Cheng is an analyst with an average return of -11.3% and a 43.75% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics, Roivant Sciences, and Ascentage Pharma Group International Unsponsored ADR.
Allogene Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.40.
Based on Allogene Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $50.94 million. In comparison, last year the company had a GAAP net loss of $66.36 million
Read More on ALLO:
Disclaimer & DisclosureReport an Issue
- Allogene Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
- Allogene Therapeutics Earnings Call: Progress Amid Challenges
- Allogene Therapeutics management to meet with Piper Sandler
- Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
